Participants may be eligible for this study if they have an early stage ovarian tumor. The purpose of the study is to evaluate the ability of two different regimens of drugs to keep early stage ovarian cancer from coming back. These drugs, paclitaxel and carboplatin, are known to be active in patients with more advanced ovarian cancer. The treatment regimen that participants receive will be determined by random chance similar to a lottery or flipping a coin.
Participants have an equal chance of being assigned to each group.
Both treatments use the drugs paclitaxel and carboplatin given by vein every three weeks for nine weeks. The drugs that participants will receive are not experimental and have been tested and shown to be effective in patients with this disease. Doctors will learn more about this disease and how to improve current treatments by patient participation in this research. The risks associated with chemotherapy administration vary according to the drugs the participant is selected to receive. There are alternatives to entering into this study, which may include additional chemotherapy or other experimental programs.